MED23 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19365750	0.49	4/20
SCHEMBL12837315	0.48	4/20
SCHEMBL13449584	0.48	4/20
SCHEMBL19669056	0.48	4/20
SCHEMBL878574	0.46	4/20
SCHEMBL20276070	0.45	4/20
SCHEMBL14340272	0.43	4/20
SCHEMBL13971295	0.58	3/20
SCHEMBL23941161	0.49	3/20
SCHEMBL14038088	0.49	3/20
SCHEMBL15216676	0.46	3/20
SCHEMBL15216663	0.45	3/20
SCHEMBL18720047	0.45	3/20
SCHEMBL22458006	0.45	3/20
SCHEMBL23407864	0.44	3/20
SCHEMBL18459799	0.42	3/20
SCHEMBL22328142	0.40	3/20
SCHEMBL22328123	0.40	3/20
SCHEMBL22328137	0.38	3/20
SCHEMBL12185010	0.60	2/20

Clinical trials — most relevant to MED23 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma	PHASE2	COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
A Study of the Genetic Analysis of Brain Disorders	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MED23 binder may also engage these)

Protein	Name	Similarity
Q5EB59	—	1.000	Q5EB59 →
Q6P423	—	1.000	Q6P423 →
Q80YQ2	—	1.000	Q80YQ2 →
Q5RIW8	—	1.000	Q5RIW8 →
Q16HH9	—	1.000	Q16HH9 →
A1Z8X3	—	1.000	A1Z8X3 →
Q80UK8	—	0.999	Q80UK8 →
P42173	—	0.999	P42173 →
Q5MNV8	—	0.998	Q5MNV8 →
Q9H0H0	—	0.997	Q9H0H0 →
Q5ZKU4	—	0.997	Q5ZKU4 →
Q9VX31	—	0.997	Q9VX31 →
Q4V847	—	0.997	Q4V847 →
Q8BKX6	—	0.996	Q8BKX6 →
Q70PP2	—	0.996	Q70PP2 →
Q18892	—	0.996	Q18892 →
Q96N11	—	0.996	Q96N11 →
Q9VE34	—	0.996	Q9VE34 →
C5J7W8	—	0.995	C5J7W8 →
Q9BVR0	—	0.995	Q9BVR0 →
Q9VXG8	—	0.994	Q9VXG8 →
Q9DE14	—	0.994	Q9DE14 →
A2A6H3	—	0.994	A2A6H3 →
GEMIN4	Gem-associated protein 4	0.994	landscape →
SMG1	Serine/threonine-protein kinase SMG1	0.993	landscape →
Q9JKK8	—	0.993	Q9JKK8 →
O08662	—	0.993	O08662 →
Q10669	—	0.993	Q10669 →
Q751Y8	—	0.993	Q751Y8 →
Q9VPF9	—	0.993	Q9VPF9 →